
Sign up to save your podcasts
Or
When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it was his family history with Alzheimer’s that motivated him.
4.6
99 ratings
When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it was his family history with Alzheimer’s that motivated him.
22,149 Listeners
111,507 Listeners
56,163 Listeners
3,497 Listeners
36 Listeners
63 Listeners
6,442 Listeners
28,397 Listeners
15,337 Listeners
20,861 Listeners
12 Listeners
7,387 Listeners
418 Listeners
1,330 Listeners
5,365 Listeners